These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 16306518)

  • 1. Neuroblastoma--from genetic profiles to clinical challenge.
    Kushner BH; Cheung NK
    N Engl J Med; 2005 Nov; 353(21):2215-7. PubMed ID: 16306518
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk-directed therapy and research in neuroblastoma.
    Liu YL; Miser JS; Hsu WM
    J Formos Med Assoc; 2014 Dec; 113(12):887-9. PubMed ID: 25499951
    [No Abstract]   [Full Text] [Related]  

  • 3. The prognostic role of urinary catecholamines in infants with disseminated neuroblastoma may be mediated by MYCN amplification.
    Parodi S; Papio F; Haupt R; Conte M; De Bernardi B
    Pediatr Blood Cancer; 2007 May; 48(5):593; author reply 593-4. PubMed ID: 16937359
    [No Abstract]   [Full Text] [Related]  

  • 4. Circulating MYCN DNA predicts MYCN-amplification in neuroblastoma.
    Combaret V; Bergeron C; Noguera R; Iacono I; Puisieux A
    J Clin Oncol; 2005 Dec; 23(34):8919-20; author reply 8920. PubMed ID: 16314658
    [No Abstract]   [Full Text] [Related]  

  • 5. [Translational research for pediatric solid malignant tumor].
    Tajiri T
    Fukuoka Igaku Zasshi; 2009 Mar; 100(3):75-80. PubMed ID: 19507538
    [No Abstract]   [Full Text] [Related]  

  • 6. Amplified MYCN in human neuroblastoma: paradigm for the translation of molecular genetics to clinical oncology.
    Schwab M
    Ann N Y Acad Sci; 2002 Jun; 963():63-73. PubMed ID: 12095930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk estimation of neuroblastoma patients using molecular markers.
    Fischer M; Spitz R; Oberthür A; Westermann F; Berthold F
    Klin Padiatr; 2008; 220(3):137-46. PubMed ID: 18478485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of SOX2 expression in neuroblastoma.
    Gómez-Mateo Mdel C; Piqueras M; Påhlman S; Noguera R; Navarro S
    Genes Chromosomes Cancer; 2011 May; 50(5):374-7. PubMed ID: 21305642
    [No Abstract]   [Full Text] [Related]  

  • 9. Circulating methylated-DCR2 gene in serum as an indicator of prognosis and therapeutic efficacy in patients with MYCN nonamplified neuroblastoma.
    Yagyu S; Gotoh T; Iehara T; Miyachi M; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tamura S; Tsuchiya K; Imamura T; Misawa-Furihata A; Sugimoto T; Sawada T; Hosoi H
    Clin Cancer Res; 2008 Nov; 14(21):7011-9. PubMed ID: 18980997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "Let's try it one more, once".
    Woods WG
    Pediatr Blood Cancer; 2006 Mar; 46(3):271-2. PubMed ID: 16078229
    [No Abstract]   [Full Text] [Related]  

  • 11. Genetic deletions help determine neuroblastoma prognosis.
    O'Hanlon LH
    Lancet Oncol; 2006 Jan; 7(1):18. PubMed ID: 16408375
    [No Abstract]   [Full Text] [Related]  

  • 12. The conundrum posed by cellular heterogeneity in analysis of human neuroblastoma.
    Ross RA; Spengler BA
    J Natl Cancer Inst; 2004 Aug; 96(16):1192-3. PubMed ID: 15316046
    [No Abstract]   [Full Text] [Related]  

  • 13. How does MYCN amplification make neuroblastomas behave aggressively? Still more questions than answers.
    Maris JM
    Pediatr Blood Cancer; 2005 Dec; 45(7):869-70. PubMed ID: 16206200
    [No Abstract]   [Full Text] [Related]  

  • 14. Biological diagnosis for neuroblastoma using the combination of highly sensitive analysis of prognostic factors.
    Tajiri T; Tanaka S; Higashi M; Kinoshita Y; Takahashi Y; Tatsuta K; Suita S
    J Pediatr Surg; 2006 Mar; 41(3):560-6. PubMed ID: 16516635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of MYCN amplified, progressive stage 4S neuroblastoma in a neonate with hepatic artery embolization in addition to multimodality treatment.
    Boztug K; Kiely E; Roebuck DJ; Gaze M; Begent J; Brock P; Michalski A
    Pediatr Blood Cancer; 2006 Feb; 46(2):253-7. PubMed ID: 15926157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study.
    Moreau LA; McGrady P; London WB; Shimada H; Cohn SL; Maris JM; Diller L; Look AT; George RE
    Clin Cancer Res; 2006 Oct; 12(19):5693-7. PubMed ID: 17020972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction.
    Gotoh T; Hosoi H; Iehara T; Kuwahara Y; Osone S; Tsuchiya K; Ohira M; Nakagawara A; Kuroda H; Sugimoto T
    J Clin Oncol; 2005 Aug; 23(22):5205-10. PubMed ID: 16051962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective study of neuroblastoma in Chinese neonates from 1994 to 2011: an evaluation of diagnosis, treatments, and prognosis : a 10-year restrospective study of neonatal neuroblastoma.
    Zhou Y; Li K; Zheng S; Chen L
    J Cancer Res Clin Oncol; 2014 Jan; 140(1):83-7. PubMed ID: 24189916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma.
    Weber A; Imisch P; Bergmann E; Christiansen H
    J Clin Oncol; 2004 Jul; 22(13):2681-90. PubMed ID: 15226335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor lysis syndrome, neuroblastoma, and correlation between serum lactate dehydrogenase levels and MYCN-amplification.
    Kushner BH; LaQuaglia MP; Modak S; Cheung NK
    Med Pediatr Oncol; 2003 Jul; 41(1):80-2. PubMed ID: 12764755
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.